<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817904</url>
  </required_header>
  <id_info>
    <org_study_id>S-4-2020</org_study_id>
    <nct_id>NCT04817904</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity</brief_title>
  <official_title>Evaluation of the Effect of Rosuvastatin on Cisplatin-induced Nephrotoxicity and Ototoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German University in Cairo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cisplatin is an effective anti-cancer drug for the treatment of many solid tumors in humans.&#xD;
      Although the clinical response to cisplatin chemotherapy is encouraging, the nephrotoxicity&#xD;
      and ototoxicity of the drug makes it difficult to continue its administration in many cases.&#xD;
&#xD;
      Cisplatin nephrotoxicity occurs through several mechanisms, mainly through the transport and&#xD;
      accumulation of cisplatin into renal epithelial cells, injury to nuclear and mitochondrial&#xD;
      DNA, activation of multiple cell death pathways and initiation of inflammatory response.&#xD;
      Accordingly, several experimental strategies were developed to prevent this toxicity. For&#xD;
      example, drugs that reduced renal cisplatin accumulation such as organic cation transporter 2&#xD;
      (OCT2) and copper transporter (Ctr1) inhibitors, antioxidants, antiapoptotic and&#xD;
      anti-inflammatory agents were investigated. However, many of these drugs interfered with the&#xD;
      cytotoxic effects of cisplatin.&#xD;
&#xD;
      Statins are agents used for reducing plasma cholesterol through the inhibition of the enzyme&#xD;
      3- hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase. In addition, statins are also&#xD;
      proven to have pleiotropic, non-lipid dependent effects. These effects include&#xD;
      anti-inflammatory actions and reduction of oxidative stress. Based on animal studies&#xD;
      performed, statins have been shown to reduce the nephrotoxic effects of cisplatin in rats. In&#xD;
      addition, ongoing clinical trials are aiming to investigate the role of statins in the&#xD;
      protection against the ototoxicity of cisplatin as well. Our aim is to assess the protective&#xD;
      effect of statins on cisplatin-induced nephrotoxicity and ototoxicity in humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of cisplatin-induced nephrotoxicity</measure>
    <time_frame>4 months</time_frame>
    <description>Increase in serum creatinine by ≥0.3 mg/dL or 1.5-2 fold increase from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in biological research markers between both arms</measure>
    <time_frame>4 months</time_frame>
    <description>Measurement of total antioxidant capacity and malondialdehyde levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in sensory-neural hearing impairment in both arms</measure>
    <time_frame>4 months</time_frame>
    <description>Audiometry assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of electrolyte imbalance in both arms</measure>
    <time_frame>4 months</time_frame>
    <description>Reduction in magnesium level ˂1.8 mg/dL and potassium level ˂3.5 mmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Cisplatin Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Statin-Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will be receiving:&#xD;
Cisplatin along with conventional nephroprotective interventions (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)&#xD;
Rosuvastatin 10 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin-Free</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will be receiving:&#xD;
-Cisplatin along with conventional nephroprotective interventions only (IV hydration with 3 liters with electrolyte replacement administered on the same day of cisplatin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10mg</intervention_name>
    <description>The statin-treated arm will receive Rosuvastatin tablets 10 mg/day starting from the point of cisplatin initiation through the entire duration of therapy</description>
    <arm_group_label>Statin-Treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven lung and breast cancer patients indicated for cisplatin (4-6&#xD;
             cycles)&#xD;
&#xD;
          -  Normal baseline serum creatinine levels&#xD;
&#xD;
          -  Normal baseline audiometry&#xD;
&#xD;
          -  Age between 18-70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with more than one type of cancer&#xD;
&#xD;
          -  Patients with prior chemotherapy treatment&#xD;
&#xD;
          -  Treatment with statins within 12 months before assignment&#xD;
&#xD;
          -  Treatment with fibrates within 4 weeks before assignment&#xD;
&#xD;
          -  Pregnancy and Lactation&#xD;
&#xD;
          -  Abnormal liver function tests or blood count&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed H Solayman, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>German University in Cairo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loay Kassem, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dalia S Elhelw, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German University in Cairo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aya T Moustafa, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>German University in Cairo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aya T Moustafa, BSc</last_name>
    <phone>+201022666179</phone>
    <email>ayatarek623@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loay Kassem, PhD</last_name>
      <phone>+201003022907</phone>
      <email>loay.kassem@cairocure.com</email>
    </contact>
    <investigator>
      <last_name>Loay Kassem, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aya T Moustafa, BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>An Y, Xin H, Yan W, Zhou X. Amelioration of cisplatin-induced nephrotoxicity by pravastatin in mice. Exp Toxicol Pathol. 2011 Mar;63(3):215-9. doi: 10.1016/j.etp.2009.12.002. Epub 2010 Jan 8.</citation>
    <PMID>20060696</PMID>
  </reference>
  <reference>
    <citation>Fujieda M, Morita T, Naruse K, Hayashi Y, Ishihara M, Yokoyama T, Toma T, Ohta K, Wakiguchi H. Effect of pravastatin on cisplatin-induced nephrotoxicity in rats. Hum Exp Toxicol. 2011 Jul;30(7):603-15. doi: 10.1177/0960327110376551. Epub 2010 Jul 22.</citation>
    <PMID>20650967</PMID>
  </reference>
  <reference>
    <citation>Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol. 2017 May 10;35(14):1506-1514. doi: 10.1200/JCO.2016.69.7391. Epub 2017 Feb 27.</citation>
    <PMID>28240967</PMID>
  </reference>
  <reference>
    <citation>Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008 May;73(9):994-1007. doi: 10.1038/sj.ki.5002786. Epub 2008 Feb 13. Review.</citation>
    <PMID>18272962</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 21, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Aya Tarek Moustafa</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cisplatin</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>nephrotoxicity</keyword>
  <keyword>ototoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ototoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

